Yipinhong Pharmaceutical Co Ltd Class A Working Capital to Net Assets Ratio
Yipinhong Pharmaceutical Co Ltd Class A working capital to net assets ratio. Yipinhong Pharmaceutical Co Ltd Class A (300723) has a Working Capital to Net Assets ratio of 32.3% as of June 2026. Working capital of CN¥607.31 Million (current assets of CN¥1.86 Billion minus current liabilities of CN¥1.25 Billion) is measured against net assets of CN¥1.88 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Yipinhong Pharmaceutical Co Ltd Class A (2013–2025)
Working capital to net assets ratio of Yipinhong Pharmaceutical Co Ltd Class A from 2013 to 2025. This chart shows how Yipinhong Pharmaceutical Co Ltd Class A's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of June 2026, the ratio stands at 32.3%, reflecting working capital of CN¥607.31 Million against net assets of CN¥1.88 Billion CNY. See Yipinhong Pharmaceutical Co Ltd Class A defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Yipinhong Pharmaceutical Co Ltd Class A Working Capital to Net Assets Ratio by Year (2013–2025)
Yipinhong Pharmaceutical Co Ltd Class A working capital to net assets ratio by year from 2013 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Yipinhong Pharmaceutical Co Ltd Class A from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see how large is Yipinhong Pharmaceutical Co Ltd Class A's balance sheet.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -2.5% | CN¥-34.66 Million | CN¥1.41 Billion | CN¥1.10 Billion | CN¥1.14 Billion | ▲ +22.0 pp |
| 2024 | -24.5% | CN¥-474.50 Million | CN¥1.94 Billion | CN¥1.26 Billion | CN¥1.73 Billion | ▼ -19.5 pp |
| 2023 | -5.0% | CN¥-129.13 Million | CN¥2.60 Billion | CN¥1.36 Billion | CN¥1.49 Billion | ▼ -14.3 pp |
| 2022 | 9.3% | CN¥202.47 Million | CN¥2.17 Billion | CN¥1.41 Billion | CN¥1.21 Billion | ▼ -8.4 pp |
| 2021 | 17.7% | CN¥357.90 Million | CN¥2.02 Billion | CN¥1.56 Billion | CN¥1.21 Billion | ▼ -25.9 pp |
| 2020 | 43.6% | CN¥652.22 Million | CN¥1.50 Billion | CN¥1.21 Billion | CN¥556.80 Million | ▼ -15.6 pp |
| 2019 | 59.2% | CN¥793.71 Million | CN¥1.34 Billion | CN¥1.18 Billion | CN¥384.33 Million | ▼ -2.0 pp |
| 2018 | 61.2% | CN¥795.43 Million | CN¥1.30 Billion | CN¥1.22 Billion | CN¥422.92 Million | ▼ -32.2 pp |
| 2017 | 93.4% | CN¥1.04 Billion | CN¥1.11 Billion | CN¥1.14 Billion | CN¥103.85 Million | ▲ +9.4 pp |
| 2016 | 84.0% | CN¥282.73 Million | CN¥336.50 Million | CN¥405.41 Million | CN¥122.68 Million | ▲ +10.3 pp |
| 2015 | 73.7% | CN¥147.87 Million | CN¥200.66 Million | CN¥278.05 Million | CN¥130.18 Million | ▲ +10.4 pp |
| 2014 | 63.3% | CN¥80.73 Million | CN¥127.52 Million | CN¥387.01 Million | CN¥306.28 Million | ▲ +101.5 pp |
| 2013 | -38.2% | CN¥-70.89 Million | CN¥185.61 Million | CN¥153.82 Million | CN¥224.71 Million | — |